tiprankstipranks
Trending News
More News >
Advertisement

XHE - ETF AI Analysis

Compare

Top Page

XHE

SPDR S&P Health Care Equipment ETF (XHE)

Rating:66Neutral
Price Target:
XHE, the SPDR S&P Health Care Equipment ETF, has a solid overall rating that reflects a mix of strong, growing companies and a few holdings facing financial or operational challenges. Positive contributors like Lemaitre Vascular, Lantheus, and Align Technology support the fund with strong financial performance, strategic growth initiatives, and promising long-term positioning, while weaker names such as DENTSPLY SIRONA, Neogen, and Masimo, which are dealing with declining revenues, profitability issues, and bearish trends, weigh on the rating. The main risk factor is that many holdings operate in the same health care equipment and related niches, so sector-specific setbacks or regulatory issues could impact several companies at once.
Positive Factors
Strong Top Holdings Performance
Several of the largest positions, such as Neogen and UFP Technologies, have shown strong gains this year, helping support the fund’s overall results.
Focused Health Care Equipment Exposure
The ETF is heavily focused on health care equipment companies, giving investors targeted exposure to a specialized and growing part of the health care sector.
Moderate Expense Ratio
The fund’s expense ratio is moderate for a specialized sector ETF, so fees are not excessively high relative to its niche focus.
Negative Factors
Single-Sector Concentration
Almost all assets are in the health care sector, which increases risk if this industry faces a downturn.
U.S.-Only Geographic Exposure
The ETF is almost entirely invested in U.S. companies, offering little diversification across global markets.
Mixed Recent Performance
While three-month returns have been strong, the ETF’s year-to-date and one-month results have been relatively weak, showing some recent volatility.

XHE vs. SPDR S&P 500 ETF (SPY)

XHE Summary

XHE is an ETF that follows the S&P Health Care Equipment Select Industry Index, focusing on U.S. companies that make medical devices, tools, and supplies used in hospitals and clinics. It holds a wide mix of health care equipment makers, including names like Neogen and Penumbra, giving you a way to invest in medical technology without picking individual stocks. Someone might consider XHE for long-term growth potential as health care needs and innovation continue to rise. However, the fund is heavily focused on one sector, so its price can swing with changes in the health care industry.
How much will it cost me?The SPDR S&P Health Care Equipment ETF (XHE) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds. However, it provides targeted exposure to the innovative health care equipment industry.
What would affect this ETF?The SPDR S&P Health Care Equipment ETF (XHE) could benefit from increased demand for innovative medical technologies and devices, driven by aging populations and advancements in health care. However, it may face challenges from regulatory changes, rising interest rates that impact growth-focused companies, or economic slowdowns that reduce health care spending. Its U.S.-focused portfolio and reliance on the health care equipment sector make it sensitive to domestic policy shifts and sector-specific trends.

XHE Top 10 Holdings

XHE is a pure play on U.S. medical devices and supplies, so health care equipment is firmly in the driver’s seat. Recent strength from names like Envista, Align Tech, and AxoGen has given the fund a lift, as these growth-oriented device makers continue to trend higher. Lantheus and Penumbra are also helping, though their signals are a bit more mixed as valuations look stretched. On the flip side, Baxter and Masimo feel more like dead weight, with ongoing financial and operational challenges keeping their stocks from fully joining the rally.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Neogen2.62%$3.50M$1.98B0.44%
50
Neutral
Lantheus2.59%$3.46M$5.14B-21.37%
73
Outperform
Lemaitre Vascular2.49%$3.33M$2.46B31.92%
75
Outperform
Masimo2.46%$3.28M$9.16B4.33%
54
Neutral
Integer Holdings2.27%$3.03M$2.86B-29.61%
65
Neutral
Envista Holdings2.25%$3.01M$4.03B47.81%
69
Neutral
Penumbra2.16%$2.89M$13.19B23.31%
78
Outperform
AxoGen2.07%$2.77M$1.68B87.48%
69
Neutral
Align Tech1.98%$2.65M$11.71B-1.18%
74
Outperform
DENTSPLY SIRONA1.98%$2.65M$2.31B-25.84%
46
Neutral

XHE Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
86.91
Negative
100DMA
86.06
Negative
200DMA
83.05
Negative
Market Momentum
MACD
-1.69
Positive
RSI
28.08
Positive
STOCH
6.34
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHE, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 85.09, equal to the 50-day MA of 86.91, and equal to the 200-day MA of 83.05, indicating a bearish trend. The MACD of -1.69 indicates Positive momentum. The RSI at 28.08 is Positive, neither overbought nor oversold. The STOCH value of 6.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XHE.

XHE Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$133.70M0.35%
66
Neutral
$996.54M0.38%
71
Outperform
$854.72M0.61%
71
Outperform
$714.09M0.40%
71
Outperform
$685.71M0.38%
69
Neutral
$395.91M0.57%
69
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XHE
SPDR S&P Health Care Equipment ETF
80.52
-3.38
-4.03%
IHE
iShares U.S. Pharmaceuticals ETF
FXH
First Trust Health Care AlphaDEX Fund
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
IHF
iShares U.S. Healthcare Providers ETF
PJP
Invesco Dynamic Pharmaceuticals ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement